Ioxaglate Versus Iodixanol for the Prevention of Contrast-induced Nephropathy in High-risk Patients (IDPC Trial)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

2262 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-12-31

Study Completion Date

2020-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Contrast media-induced nephropathy following diagnostic and therapeutic cardiac catheterization.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention

NCT04806633

Left Cardiac Catheterization Percutaneous Coronary Intervention Acute Kidney Injury +1 more

UNKNOWN EARLY_PHASE1

Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography

NCT00209430

Coronary Artery Disease Renal Impairment

COMPLETED PHASE4

Interest of Remote Ischemic Preconditioning for Prevention of Contrast Medium-induced Nephropathy in High Risk Patients

NCT02470247

Nephropathy

COMPLETED NA

Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST)

NCT00390585

Renal Insufficiency, Chronic Angioplasty, Transluminal, Percutaneous Coronary Coronary Arteriosclerosis

COMPLETED PHASE4

Biochemical Effects of Remote Ischemic Pre-Conditioning on Contrast-induced Acute Kidney Injury

NCT03236441

Contrast-induced Acute Kidney Injury

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Contrast-induced acute kidney injury represents a serious complication of procedures requiring administration of iodinated contrast media and is associated with the need for dialysis, prolonged hospitalization, increased costs, and mortality.

Contrast-induced nephropathy is defined as an increase of 25% in serum creatinine before the procedure.

Iodixanol, a nonionic, dimeric, iso-osmolar contrast medium may be less nephrotoxic than low-osmolar contrast media in high-risk patients.

The purpose of this study is to compare iodixanol versus ioxaglate in high risk patients between 48 and 96 hours after procedures that use contrast.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Kidney Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Iodixanol

Iodixanol contrast media

contrast media

Intervention Type OTHER

Compare 2 contrast media

Ioxaglate

Ioxaglate contrast media

contrast media

Intervention Type OTHER

Compare 2 contrast media

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

contrast media

Compare 2 contrast media

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Iodixanol X Ioxaglate

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

At least one of the following criteria

* Aged more than 70 years-old
* Chronic renal failure
* Diabetes mellitus
* Congestive heart failure - left ventricular ejection fraction \< 0.50
* Shock or intra-aortic ballon pump use
* Urgency or emergency procedures